|
|
|
About Dendritic Nanotechnologies Inc. (DNT)
DNT is a premier developer and provider of advanced dendritic polymers. DNT provides business partners with innovative dendrimer technologies and commercialization services based on its new proprietary Priostar dendrimer technologies. DNT’s Priostar dendrimers are the newest family of dendrimers and were engineered to be commercially viable (reduced manufacturing complexity and costs). DNT has Priostar dendrimer products for use in many industrial, cosmetic, life sciences reagents, and special chemical sectors with applications as diverse as adhesives, lubricants, UV curable additives, cosmetic additives, and water remediation chelators. Products based on DNT’s dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.
DNT’s proprietary Priostar and STARBURST dendrimer products have also been designed to be used in the pharmaceutical sector as a targeted diagnostic and therapeutic delivery systems for a wide variety of drugs to cancer cells and other diseases. Improved efficacy, enhanced solubility, and lower toxicity have been demonstrated for a number of existing drugs.
The company has patents pending on its Priostar family of dendrimers. Priofect™, Priostar™ and STARBURST® are trademarks of Dendritic Nanotechnologies.
Dendritic Nanotechnologies, Inc. is a wholly owned U.S. based operating company of Starpharma Holdings, Ltd., and is located in Mount Pleasant, Michigan.
About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA.
The Company’s lead pharmaceutical development product is VivaGel™ (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
In the pharmaceutical field Starpharma has additional specific programs in the areas of Drug Delivery and ADME Engineering™ (using dendrimers to control where and when drugs go when introduced to the body), Polyvalency (using the fact that dendrimers can activate multiple receptors simultaneously) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signalling and targeting groups are added to allow location of specific cell type, such as cancer cells).
See www.starpharma.com
American Depositary Receipts (ADRs)
Starpharma’s ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank. |
|
|
Online ordering of STARBURST® dendrimers now available.
06-25-2008
First commercial product launch of Starpharma’s DNT Priostar® Dendrimers
- EMD Chemicals Inc. launches DNA Transfection Reagent Kit -
04-22-2008
Starpharma signs agreement with Unilever
04-07-2008
New Lower Pricing on STARBURST® PAMAM Dendrimers
02-26-2008
Oncologix Tech, Inc. and Dendritic Nanotechnologies, Inc. Resolve Leaching Issues with the Oncosphere Product
08-22-2007
|
PDF(0.3MB)
